Keymed Biosciences Co.Ltd
Headquarters country
Cayman Islands
Registry sponsor category
Industry
- Other names
- Keymed Biosciences Co.Ltd
- Company name
- Keymed Biosciences Co.Ltd
- Organisation type
- Industry
- Registered legal name
- KEYMED BIOSCIENCES INC.
- Registry sponsor category
- Industry
- Legal Entity Identifier (LEI)
- 549300600S6M6SOT7P36
Related records
Trials (67)
- A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.
- A Multiple Ascending Doses Study of CM326 Injection in Healthy Subjects
- A Study of CM310 in Children Patients With Moderate-to-severe Atopic Dermatis
- A Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （CROWNS-2）
- A Study of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis
- A Study of CM310 in Subjects With Chronic Pruritus
- A Study of CM310 in Subjects With Moderate to Severe Asthma
- A Study of CM310 in Subjects With Moderate-to-Severe Atopic Dermatitis
- A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma
- A Study of CM313 Injection in Subjects With Systemic Lupus Erythematosus
- A Study of CM326 in Patients With Chronic Rhinosinusitis With Nasal Polyps
- A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia
- A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma
- A Study of CM350 in Patients With Advanced Solid Tumors
- A Study of CM383 in Patients With Alzheimer's Disease Related Mild Cognitive Impairment and Mild Alzheimer's Disease
- A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （NEZHA-2）
- A Study of CM512 in Subjects With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
- A Study of Stapokibatrt in Children Subjects With Atopic Dermatitis
- BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy
- BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma